Kymera Therapeutics (KYMR) Receivables - Net (2020 - 2026)

Kymera Therapeutics (KYMR) has reported Receivables - Net for 6 consecutive years, with $40.0 million the latest figure, recorded in Q2 2025.

• In Q2 2025, Receivables - Net rose 2247.42% year-over-year to $40.0 million; the TTM figure through Jun 2025 stood at $40.0 million (up 2247.42% YoY), while the FY2024 annual figure was $947000.0, down 94.95% from the prior year.
• Receivables - Net climbed to $40.0 million in Q2 2025 per KYMR's latest filing, from $20.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $40.0 million in Q2 2025 and bottomed at $135000.0 in Q4 2021.
• Historically, Receivables - Net has averaged $6.1 million across 5 years, with a median of $2.2 million in 2022.
• Annual changes were most pronounced in 2024 — Receivables - Net sank 94.95% — and 2025, when it jumped 2247.42%.
• Kymera Therapeutics' Receivables - Net stood at $135000.0 in 2021, then soared by 1779.26% to $2.5 million in 2022, then soared by 639.53% to $18.8 million in 2023, then tumbled by 94.95% to $947000.0 in 2024, then soared by 4123.86% to $40.0 million in 2025.
• Business Quant data shows KYMR's Receivables - Net at $40.0 million in Q2 2025, $20.0 million in Q1 2025, and $947000.0 in Q4 2024.